In addition to George Tidmarsh, 3 other LJPC executives reported Buy trades in the last month.
Based on La Jolla Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.47 million and GAAP net loss of $50.75 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $38.55 million. Currently, La Jolla Pharma has an average volume of 4.83M.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $30.33, reflecting a 398.0% upside. Starting in October 2018, LJPC received 4 Buy ratings in a row.
In the last 30 days, insiders have sold $11.72M worth of LJPC shares and purchased $52.24K worth of LJPC shares.
George Tidmarsh’s trades have generated a 125.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
Read More on LJPC: